NASDAQ:GELS Gelteq (GELS) Stock Price, News & Analysis $0.61 +0.02 (+2.90%) Closing price 07/17/2026 03:58 PM EasternExtended Trading$0.58 -0.02 (-3.81%) As of 07/17/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Gelteq Stock (NASDAQ:GELS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gelteq alerts:Sign Up Key Stats Today's Range$0.43▼$0.6250-Day Range$0.39▼$1.5352-Week Range$0.39▼$2.02Volume260,673 shsAverage Volume94,634 shsMarket Capitalization$6.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK. Read More Gelteq Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreGELS MarketRank™: Gelteq scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGelteq has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGelteq has only been the subject of 1 research reports in the past 90 days.Read more about Gelteq's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGelteq has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.56% of the float of Gelteq has been sold short.Short Interest Ratio / Days to CoverGelteq has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gelteq has recently decreased by 60.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGelteq does not currently pay a dividend.Dividend GrowthGelteq does not have a long track record of dividend growth. News and Social Media2.4 / 5News SentimentN/A News SentimentGelteq has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Gelteq this week, compared to 2 articles on an average week.Search Interest3 people have searched for GELS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gelteq insiders have not sold or bought any company stock.Percentage Held by InstitutionsGelteq has minimal institutional ownership at this time.Read more about Gelteq's insider trading history. Receive GELS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelteq and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GELS Stock News HeadlinesGelteq Limited (NASDAQ:GELS) Sees Large Decline in Short InterestJuly 13, 2026 | americanbankingnews.comGelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel TechnologyJuly 2, 2026 | stockhouse.comYour First Trade Playbook is expiringMost beginners stay stuck on the sidelines for years because no one shows them the simple steps between being interested in options and actually placing a trade. Your First Trade Playbook closes that gap in one evening - and right now it is still free. Bill Poulos plans to charge for it soon, so download your copy before the temporary link expires.July 18 at 1:00 AM | Profits Run (Ad)Gelteq Limited Advances Clinical Programs and Asia Expansion in First Half of 2026June 30, 2026 | tipranks.comGelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple ProgramsJune 17, 2026 | globenewswire.comGelteq Limited: Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health ApplicationsJune 13, 2026 | finanznachrichten.deWhat's going on with Gelteq stock Friday?June 12, 2026 | msn.comGelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health ApplicationsJune 12, 2026 | globenewswire.comSee More Headlines GELS Stock Analysis - Frequently Asked Questions How have GELS shares performed this year? Gelteq's stock was trading at $0.80 at the beginning of 2026. Since then, GELS stock has decreased by 24.2% and is now trading at $0.6061. How were Gelteq's earnings last quarter? Gelteq Limited (NASDAQ:GELS) announced its earnings results on Tuesday, June, 30th. The company reported ($0.12) EPS for the quarter. When did Gelteq IPO? Gelteq (GELS) raised $5 million in an initial public offering (IPO) on Tuesday, October 29th 2024. The company issued 1,300,000 shares at a price of $4.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Gelteq? Shares of GELS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/30/2026Today7/18/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 2 weeks, GELS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GELS Previous SymbolNASDAQ:GELS CIK1920092 Webwww.gelteq.com Phone61-3-9087-3990FaxN/AEmployeesN/AYear Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick RatioN/A Sales & Book Value Annual Sales$110 thousand Price / Sales59.01 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book0.56Miscellaneous Outstanding Shares10,710,000Free FloatN/AMarket Cap$6.49 million OptionableN/A Beta-0.55 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GELS) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored#1 Question to Ask Your Bank TodayElon Musk's new banking platform is paying up to 15 times the national average interest rate while insuring de...InvestorPlace | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredAI investors should get ready for a BIG surpriseWall Street insider Jason Bodner - who called Nvidia at $4.50 - says today's most popular AI stocks are about ...Brownstone Research | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
